Abstract: SCIENCE CHINA
Life Sciences
•LETTER TO THE EDITOR•
April 2021 Vol.64 No.4: 660–663
https://doi.org/10.1007/s11427-020-1871-4
Evaluation of the efficacy and safety of hydroxychloroquine in
comparison with chloroquine in moderate and severe patients with
COVID-19
1†
2†
3†
4
5
6
7
Qiuyu Li , Cheng Cui , Fei Xu , Jianping Zhao , Nan Li , Haichao Li , Tianbing Wang ,
5
2,8
2
2
2
8
2
Hua Zhang , Na Liu , Yudong Wei , Xiaoye Niu , Yan Xu , Jianping Dong , Xueting Yao ,
1
1
2,9
10
10
2*
Xiaohong Wang , Yahong Chen , Haiyan Li , Chunli Song , Jie Qiao , Dongyang Liu &
1*
Ning Shen
1
Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China;
2
Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China;
3
Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China;
4
Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan 430030, China;
5
Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China;
6
Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China;
7
Trauma Center, Peking University People’s Hospital, Beijing 100044, China;
8
Beijing Haidian Hospital, Haidian Section of Peking University Third Hospital, Beijing 100080, China;
9
Department of Cardiology, Peking University Third Hospital, Beijing 100191, China;
10
Institute of Medical Innovation, Peking University Third Hospital, Beijing 100191, China
Received August 19, 2020; accepted December 18, 2020; published online January 18, 2021
Citation:
Li, Q., Cui, C., Xu, F., Zhao, J., Li, N., Li, H., Wang, T., Zhang, H., Liu, N., Wei, Y., et al. (2021). Evaluation of the efficacy and safety of
hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19. Sci China Life Sci 64, 660–663. https://doi.org/
10.1007/s11427-020-1871-4
Dear Editor,
Since December 2019, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has been rapidly spreading
worldwide. Hydroxychloroquine and chloroquine are candidates for the treatment of coronavirus disease 2019
(COVID-19) owing to its antiviral effect and immunomodulation properties. However, the published results
of utilizing hydroxychloroquine and chloroquine as treatment were still controversial and their efficacy and safety in
patients with COVID-19 need to be further elucidated.
A total of 88 laboratory-confirmed (identified by viral
†Contributed equally to this work
*Corresponding authors (Ning Shen, email: shenning1972@126.com; Dongyang Liu,
email: liudongyang@vip.sina.com)
RNA or antibody tests) patients with COVID-19 (65 moderate and 23 severe patients with COVID-19) were included
in our multicenter, randomized controlled trial (RCT). Eligible patients randomly assigned in a 1:1 ratio to orally receive hydroxychloroquine (600 mg twice a day on the first
day followed by 200 mg twice a day in the last four days)
plus standard care or chloroquine (500 mg twice a day for the
first three days followed by 250 mg twice a day in the last
two days) plus standard care (SC) for 5 days. Our study
protocol is provided in the Supplementary Methods. The
average age of our patients was 61.3 years old and they had a
higher risk of developing severe illness. The average time
interval..
DOI record:
{
"DOI": "10.1007/s11427-020-1871-4",
"ISSN": [
"1674-7305",
"1869-1889"
],
"URL": "http://dx.doi.org/10.1007/s11427-020-1871-4",
"alternative-id": [
"1871"
],
"assertion": [
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Received",
"name": "received",
"order": 1,
"value": "19 August 2020"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Accepted",
"name": "accepted",
"order": 2,
"value": "18 December 2020"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "First Online",
"name": "first_online",
"order": 3,
"value": "18 January 2021"
},
{
"label": "Free to read",
"name": "free",
"value": "This content has been made available to all."
}
],
"author": [
{
"affiliation": [],
"family": "Li",
"given": "Qiuyu",
"sequence": "first"
},
{
"affiliation": [],
"family": "Cui",
"given": "Cheng",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Xu",
"given": "Fei",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhao",
"given": "Jianping",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Li",
"given": "Nan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Li",
"given": "Haichao",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wang",
"given": "Tianbing",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhang",
"given": "Hua",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Liu",
"given": "Na",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wei",
"given": "Yudong",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Niu",
"given": "Xiaoye",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Xu",
"given": "Yan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Dong",
"given": "Jianping",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Yao",
"given": "Xueting",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wang",
"given": "Xiaohong",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Chen",
"given": "Yahong",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Li",
"given": "Haiyan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Song",
"given": "Chunli",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Qiao",
"given": "Jie",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Liu",
"given": "Dongyang",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Shen",
"given": "Ning",
"sequence": "additional"
}
],
"container-title": "Science China Life Sciences",
"container-title-short": "Sci. China Life Sci.",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"link.springer.com"
]
},
"created": {
"date-parts": [
[
2021,
1,
20
]
],
"date-time": "2021-01-20T16:03:24Z",
"timestamp": 1611158604000
},
"deposited": {
"date-parts": [
[
2021,
4,
7
]
],
"date-time": "2021-04-07T03:38:57Z",
"timestamp": 1617766737000
},
"indexed": {
"date-parts": [
[
2023,
2,
11
]
],
"date-time": "2023-02-11T12:52:59Z",
"timestamp": 1676119979163
},
"is-referenced-by-count": 2,
"issue": "4",
"issued": {
"date-parts": [
[
2021,
1,
18
]
]
},
"journal-issue": {
"issue": "4",
"published-print": {
"date-parts": [
[
2021,
4
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://www.springer.com/tdm",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
1,
18
]
],
"date-time": "2021-01-18T00:00:00Z",
"timestamp": 1610928000000
}
},
{
"URL": "http://www.springer.com/tdm",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
1,
18
]
],
"date-time": "2021-01-18T00:00:00Z",
"timestamp": 1610928000000
}
}
],
"link": [
{
"URL": "http://link.springer.com/content/pdf/10.1007/s11427-020-1871-4.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "http://link.springer.com/article/10.1007/s11427-020-1871-4/fulltext.html",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "http://link.springer.com/content/pdf/10.1007/s11427-020-1871-4.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "297",
"original-title": [],
"page": "660-663",
"prefix": "10.1007",
"published": {
"date-parts": [
[
2021,
1,
18
]
]
},
"published-online": {
"date-parts": [
[
2021,
1,
18
]
]
},
"published-print": {
"date-parts": [
[
2021,
4
]
]
},
"publisher": "Springer Science and Business Media LLC",
"reference": [
{
"DOI": "10.1056/NEJMoa2002032",
"author": "WJ Guan",
"doi-asserted-by": "publisher",
"first-page": "1708",
"journal-title": "N Engl J Med",
"key": "1871_CR1",
"unstructured": "Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, D.S.C., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382, 1708–1720.",
"volume": "382",
"year": "2020"
},
{
"DOI": "10.1016/S0140-6736(20)30183-5",
"author": "C Huang",
"doi-asserted-by": "publisher",
"first-page": "497",
"journal-title": "Lancet",
"key": "1871_CR2",
"unstructured": "Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2001316",
"author": "Q Li",
"doi-asserted-by": "publisher",
"first-page": "1199",
"journal-title": "N Engl J Med",
"key": "1871_CR3",
"unstructured": "Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S.M., Lau, E.H.Y., Wong, J.Y., et al. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382, 1199–1207.",
"volume": "382",
"year": "2020"
},
{
"DOI": "10.1016/j.ebiom.2020.102763",
"author": "J Liu",
"doi-asserted-by": "publisher",
"first-page": "102763",
"journal-title": "EBioMedicine",
"key": "1871_CR4",
"unstructured": "Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al. (2020). Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55, 102763.",
"volume": "55",
"year": "2020"
},
{
"DOI": "10.1038/s41577-020-0304-7",
"author": "C Moon",
"doi-asserted-by": "publisher",
"first-page": "277",
"journal-title": "Nat Rev Immunol",
"key": "1871_CR5",
"unstructured": "Moon, C. (2020). Fighting COVID-19 exhausts T cells. Nat Rev Immunol 20, 277.",
"volume": "20",
"year": "2020"
},
{
"DOI": "10.1182/blood-2011-01-329060",
"author": "S Piconi",
"doi-asserted-by": "publisher",
"first-page": "3263",
"journal-title": "Blood",
"key": "1871_CR6",
"unstructured": "Piconi, S., Parisotto, S., Rizzardini, G., Passerini, S., Terzi, R., Argenteri, B., Meraviglia, P., Capetti, A., Biasin, M., Trabattoni, D., et al. (2011). Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 118, 3263–3272.",
"volume": "118",
"year": "2011"
},
{
"DOI": "10.1093/cid/ciaa248",
"author": "C Qin",
"doi-asserted-by": "publisher",
"first-page": "762",
"journal-title": "Clin Infect Dis",
"key": "1871_CR7",
"unstructured": "Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020). Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 71, 762–768.",
"volume": "71",
"year": "2020"
},
{
"DOI": "10.1111/jth.14768",
"author": "N Tang",
"doi-asserted-by": "publisher",
"first-page": "844",
"journal-title": "J Thromb Haemost",
"key": "1871_CR8",
"unstructured": "Tang, N., Li, D., Wang, X., and Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18, 844–847.",
"volume": "18",
"year": "2020"
},
{
"DOI": "10.1136/bmj.m1849",
"author": "W Tang",
"doi-asserted-by": "publisher",
"first-page": "1849",
"journal-title": "BMJ",
"key": "1871_CR9",
"unstructured": "Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020). Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369, m1849.",
"volume": "369",
"year": "2020"
},
{
"DOI": "10.1016/j.clim.2018.07.003",
"author": "M Torigoe",
"doi-asserted-by": "publisher",
"first-page": "1",
"journal-title": "Clin Immunol",
"key": "1871_CR10",
"unstructured": "Torigoe, M., Sakata, K., Ishii, A., Iwata, S., Nakayamada, S., and Tanaka, Y. (2018). Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol 195, 1–7.",
"volume": "195",
"year": "2018"
},
{
"DOI": "10.1038/s41577-020-0305-6",
"author": "N Vaninov",
"doi-asserted-by": "publisher",
"first-page": "277",
"journal-title": "Nat Rev Immunol",
"key": "1871_CR11",
"unstructured": "Vaninov, N. (2020). In the eye of the COVID-19 cytokine storm. Nat Rev Immunol 20, 277.",
"volume": "20",
"year": "2020"
},
{
"DOI": "10.1016/S0140-6736(20)30566-3",
"author": "F Zhou",
"doi-asserted-by": "publisher",
"first-page": "1054",
"journal-title": "Lancet",
"key": "1871_CR12",
"unstructured": "Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062.",
"volume": "395",
"year": "2020"
}
],
"reference-count": 12,
"references-count": 12,
"relation": {},
"resource": {
"primary": {
"URL": "http://link.springer.com/10.1007/s11427-020-1871-4"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"General Agricultural and Biological Sciences",
"General Environmental Science",
"General Biochemistry, Genetics and Molecular Biology"
],
"subtitle": [],
"title": "Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
"volume": "64"
}
